Diagnostic accuracy of screening tools for chronic obstructive pulmonary disease in primary health care: Rapid evidence synthesis

Jyoti Tyagi, Sandeep Moola, Soumyadeep Bhaumik

The George Institute for Global Health, New Delhi, India

ABSTRACT

Background: Chronic obstructive pulmonary disease (COPD) contributed significantly to burden of diseases in India, with missed, incorrect, and delayed diagnosis in primary care. We conducted a rapid evidence synthesis, to summarize the evidence on accuracy of the screening tests for COPD in primary health care on request from State Health Resource Centre, Chhattisgarh. Methods: Considering the rapid nature of decision making, our approach was to first search for existing systematic reviews. We identified one existing systematic review on the topic with the search conducted until 2014. We updated the review by searching in two major databases screened, title/abstracts, and full texts of studies as per eligibility criteria and extracted relevant data. A narrative synthesis was conducted. Results: We retrieved 7,007 and included five new studies, to add to 10 studies of the existing systematic review. Overall, 13 studies assessed diagnostic accuracy of screening questionnaires [e.g., COPD Diagnostic Questionnaire (CDQ)], five assessed handheld flow meters (COPD6 and PICO-6), and four assessed the combination of both the tests. The CDQ questionnaire using a score threshold ≥16.5 or >17 demonstrated comparatively a higher sensitivity both in pooled result for ever-smokers [87.5% (95% CI 83.1–90.9%)] and among the adults >35 years [73.8–93% (95% CI 69–98%)] when compared to a different score threshold of CDQ and other questionnaires. Handheld flow meters reported a pooled high sensitivity of 79.9% (95% CI 74.2–84.7%) in ever-smokers and 87.9% in adults with age >35 years. Conclusions: The need for better diagnosis of COPD in primary healthcare can be addressed by using of COPD Diagnostic Questionnaire alone or in combination with hand-held flow meters. There is scope for more implementation research on the domain.

Keywords: Chronic obstructive pulmonary disease, diagnostic test accuracy, primary health care, screening, sensitivity, specificity, spirometry
care. Globally it is known that primary care providers often missed early diagnosis of COPD, when symptoms are mild and the disease is often diagnosed at an advanced stage, when lung changes are no longer fully reversible.\(^\text{5}\)

We received a request from SHRC to conduct a review of the evidence (within 6 weeks) on screening tests for diagnosing COPD in primary healthcare facilities.

## Methods

### Approach for the study

Based on an initial scoping of literature, we identified a systematic review\(^6\) published in 2015 which address the review question of interest. It provided relevant details from included studies (published until 2014) on diagnostic accuracy of screening tests for identifying undiagnosed COPD. Hence, our approach was updating the systematic review\(^6\) by searching for studies of any quantitative design that evaluated screening tests conducted in PHC.

### Ethical approval

The article is a review of published literature and did not involve any living participant. As such, no ethical approval was necessary.

### Eligibility criteria

We included studies which met the following criteria:

1. **Population:** Studied which included individuals aged ≥35 years with no prior diagnosis of COPD.
2. **Index test:** Screening questionnaires (any), handheld flow meters/handheld spirometer (e.g., Piko-6 or COPD-6), peak flow meters/micro spirometry, risk prediction models, decision aids, and chest radiography, either used alone or in combination with any of the aforementioned tests.
3. **Reference Standard:** Presence of airflow obstruction measured by prebronchodilator or postbronchodilator spirometry.
4. **Diagnosis of interest:** Identification of COPD.
5. **Study design:** Studies of any quantitative design.
6. **Setting:** Studies conducted in PHC context (including general practices and community pharmacies) were considered.

### Information sources

We searched two electronic databases (Medline and EMBASE) from January 2014 to March 2020 [Appendix 1]. The search was restricted to studies published in the English language.

### Study selection

We retrieved 7,007 articles after electronic databases search. Following the removal of one duplicate, the titles/abstracts of 7,006 studies were screened based on the pre-set eligibility criteria. Full texts of 44 potentially eligible articles were obtained and were reviewed for further examination. Only five of the 44 studies were included in the final report.

We thus added five new studies\(^17\) to the existing 10 studies\(^7\) of the systematic review by Haroon et al\(^9\) Figure 1 depicts the study selection process in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.

### Study characteristics

The review reported 10 studies\(^7\) from existing systematic review\(^6\) and additional five studies\(^17\) were supplemented with updated search. Overall, 15 studies\(^7\) accounting for 35,429 participants were included in the review. The review examined evidence on diagnostic accuracy of screening tests mainly measured by sensitivity and specificity of the test for detecting COPD. Majority of the studies were of cross-sectional diagnostic test accuracy design. The mean age of the participants ranged from 49 years to 69.5 years. Most of the studies were conducted in developed countries like UK, US, Australia, European countries, except one\(^8\) which was conducted in Vietnam. Four studies\(^10,13,14,19\) used a paired design and compared two screening tests (screening questionnaires and handheld flow meters), while the remaining studies used single screening method followed by spirometry as reference test. Meta-analyses were conducted in five\(^10,12,14,16\) studies from the systematic review by Haroon et al\(^9\).

Rest of the studies were excluded from the meta-analyses on the account of heterogeneity in the studies. The methodological quality of 10 studies from the systematic review was assessed.

### Data collection process

A pre-designed template for data extraction was developed. The primary reviewer independently extracted all relevant outcome data. We extracted data on several key parameters including: 1) Study type, 2) Countries where studies were conducted, 3) Participants (number) and details of setting, 4) Index and reference tests, 5) Outcome measures (sensitivity and specificity).

### Synthesis of results

Relevant outcome data were extracted and tabulated from selected reviews. A narrative synthesis was presented that addressed the review question documenting the relevant data and findings from all\(^7\) the included studies. The findings of meta-analyses conducted in the existing systematic review\(^6\) were presented, wherever relevant. On account of considerable heterogeneity, additional five\(^17\) studies were precluded from meta-analyses.

We used the PRISMA extension for Diagnostic Test Accuracy (DTA) [Appendix 2] for reporting the study.

### Results

#### Study selection

We retrieved 7,007 articles after electronic databases search. Following the removal of one duplicate, the titles/abstracts of 7,006 studies were screened based on the pre-set eligibility criteria. Full texts of 44 potentially eligible articles were obtained and were reviewed for further examination. Only five of the 44 studies were included in the final report.

We thus added five new studies\(^17\) to the existing 10 studies\(^7\) of the systematic review by Haroon et al\(^9\). Figure 1 depicts the study selection process in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.

#### Study characteristics

The review reported 10 studies\(^7\) from existing systematic review\(^6\) and additional five studies\(^17\) were supplemented with updated search. Overall, 15 studies\(^7\) accounting for 35,429 participants were included in the review. The review examined evidence on diagnostic accuracy of screening tests mainly measured by sensitivity and specificity of the test for detecting COPD. Majority of the studies were of cross-sectional diagnostic test accuracy design. The mean age of the participants ranged from 49 years to 69.5 years. Most of the studies were conducted in developed countries like UK, US, Australia, European countries, except one\(^8\) which was conducted in Vietnam. Four studies\(^10,13,14,19\) used a paired design and compared two screening tests (screening questionnaires and handheld flow meters), while the remaining studies used single screening method followed by spirometry as reference test. Meta-analyses were conducted in five\(^10,12,14,16\) studies from the systematic review by Haroon et al\(^9\).

Rest of the studies were excluded from the meta-analyses on the account of heterogeneity in the studies. The methodological quality of 10 studies from the systematic review was assessed.

---

Journal of Family Medicine and Primary Care 2021 Volume 10 : Issue 6 : June 2021
using QUADAS-2 tool, however, the additional five studies were not appraised. Key characteristics of all the included studies are presented in Appendix 3.

Index and reference tests

Index tests included screening questionnaires ($n = 13$) and handheld flow meters ($n = 6$). Prebronchodilator spirometry was used as the reference standard test in two studies while 13 studies used both pre and postbronchodilator spirometry.

Screening questionnaires

Thirteen studies assessed four screening questionnaires on 15,182 participants. Among all the questionnaires, the CDQ was the most widely used screening tool ($n = 8$) followed by other screening questionnaires. The CDQ is also referred to as the Respiratory Health Screening Questionnaire (RHSQ) or International Primary Care Airways Group (IPAG) questionnaire. Few studies reported using more than one questionnaire as their screening tool.

No new studies were found which had evaluated CDQ as screening tool (using a threshold of $\geq 19.5$, $\geq 16.5$ or $>17$) in ever-smokers and the meta-analysis of four studies was done by the Haroon et al. Remaining studies were precluded from conducting meta-analysis as a result of the heterogeneity in their threshold of score and the participants. The pooled sensitivity and specificity reported for the score threshold of $\geq 19.5$ was 64.5% [95% Confidence Interval (CI) 59.9–68.8%] and 65.2% (95% CI 52.9–75.8%), respectively. While the pooled sensitivity reported for the score threshold of $\geq 16.5$ was higher at 87.5% (83.1 to 90.9), the specificity was quite low at 38.8% (27.7 to 51.3).

The un-pooled sensitivities and specificities in adults $>35$ years and ever-smokers for different threshold score were reported separately [Table 1]. At a score threshold of $<19.5$, the sensitivity and specificity reported was 36% (CI 11–61%) and 93% (CI 89–96%), respectively. The sensitivities and specificities using a score threshold $\geq 19.5$ ranged from 59 to 73% and 54 to 77%, respectively. At a score threshold $\geq 16.5$ or $\geq 17$, the sensitivities ranged from 73.8 to 93%, while specificities were reported in the range of 24–57%.

Figure 1: The study selection process in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram
The pooled\cite{10,12,14,15,16} result for ever-smokers and among the adults >35 years\cite{10,12,14,16,18,21} reported a comparative high sensitivity for COPD diagnostic questionnaire (CDQ) using a score threshold ≥16.5 or >17 as compared to a different score threshold of CDQ and other questionnaires signifying a lower percentage of missed positive cases [as summarized in Table 1]. Likewise, the pooled Negative Predictive Value (NPV) of CDQ reported at the same threshold score 98.2% probability that the subject with negative result is truly free of disease.

Studies using Lung Function Questionnaire (LFQ), COPD Population Screener (COPD-PS), and Two screening questions (2SQ) reported a significant heterogeneity in their design, and therefore were not eligible to be included in a meta-analysis.

The COPD-PS screening questionnaire across the three studies\cite{18-20} in adults >35 years reported (using a score threshold ≥4 or ≥5) sensitivities ranging from 20 to 80.4% and specificities from 47.7 to 90.8%, respectively.

Lung Function Questionnaire\cite{11,13,15,20} at a score of ≤18 reported sensitivity ranging from 79 to 93% which was again suggestive of a lower percentage of missed positive cases while the specificity reported was between the range of 25 and 71%.

Other screening questionnaires were assessed in = 2 studies\cite{7,9} which reported sensitivity range of 57–87% and specificity ranging between 71–80%.

### Handheld flow meter

Handheld flowmeter is a device intended for measuring lung function. FEV1 and FEV6 is a measure of forced expiratory volume in 1 and 6 s, respectively. The test is repeated three times with the highest values recorded. Five studies evaluated the diagnostic accuracy of handheld flow meter in 2,052 participants.\cite{8,10,15,16,18,19}

The mean age of the participants ranged from 52 to 65.3 years. Four studies used it without a bronchodilator.\cite{8,10,16,18,19} The handheld meter used were COPD6 and PICO-6. An FEV1/FEV6 cut off <0.7 provided a range of sensitivity from 79 to 87.9% and specificity from 71 to 99% for COPD screening.

Three studies\cite{10,15,16} enrolling ever-smokers from the existing systematic review\cite{8} were deemed eligible for conducting meta-analysis as a result of their homogeneity. Handheld flow meters\cite{10,15,16} when used under the supervision of trained nurses and health professionals reported a pooled high sensitivity of 79.9% (95% CI 74.2–84.7%) and a specificity of 84.4% (95% CI 68.9–93.0%), respectively [Table 1].

In adults with age >35 years and ever-smokers, the un-pooled\cite{8,10,15,16,18,19} sensitivities and specificities were reported in the range of 79–87.9% and 71–99%, respectively.

### Table 1: Accuracy of Different Diagnostic Tests for COPD\cite{2-21}

| Screening test                        | Sensitivity (95% CI)* | Specificity (95% CI)* | PPV (95% CI)* | NPV (95% CI)* | NNS OR NND* (95% CI) |
|---------------------------------------|------------------------|------------------------|---------------|---------------|---------------------|
| Narrative Synthesis with Pre and Post bronchodilator spirometry as reference test in adults >35 years | | | | | |
| CDQ (using a score threshold <19.5)\cite{7} | 36 (11-61) | 93 (89-96) | NR | NR | NR |
| CDQ (using a score threshold ≥19.5)\cite{10,12,14,21} | 59-73% | 54-77% | NR | NR | NR |
| CDQ (using a score threshold ≥16.5 or ≥17)\cite{10,12,14,15,18,20} | 73.8-93% | 24-57% | NR | NR | NR |
| COPD-PS (using a score threshold ≥4 or ≥5)\cite{18-20} | 20-80.4% | 47.7-90% | 5.3-41% | 87.2-94.3% | NR |
| LFQ (using a score of ≤18)\cite{11,13,15,20} | 79-93% | 25-71% | NR | NR | NR |
| Other unnamed questionnaires\cite{7,9} | 57-87% | 71-80% | NR | NR | NR |
| Handheld flow meter\cite{10,11,14,15} | 79-87.9% | 71-99% | NR | NR | NR |
| CDQ and handheld flow meter\cite{11} used together | 74.4 (64.2-83.1) | 97.0 (95.2-98.3) | 59.1 (43.8-74.0) | 98.5 (97.9-99.0) | NNS-25 (22-29); NND-2 (2-3) |
| COPD-PS and handheld flow meter\cite{10} used together | 20% | 92.9% | 14.3% | 95.1% | NR |

NR- Not Reported. *Sensitivity - ability of a test to correctly identify those with the disease (true positive), Specificity - ability of the test to correctly identify those without the disease (true negative), PPV - Positive Predictive Value - Chances that patients with a positive test truly have the disease, NPV - Negative Predictive Value - Chances that patients with a negative test truly don't have the disease, NND- Number needed to diagnose: number of patients needing a diagnostic assessment to identify one patient with COPD (the lower the number better the yield), NNS- Number needed to screen - number of individuals who needed-to-be-screened to identify one patient with COPD (the lower the number better the yield). The pooled results reported are from the studies of existing systematic review\cite{8}. CDQ COPD Diagnostic Questionnaire is also referred as the International Primary Airways Group (IPAG) Questionnaire or Respiratory Health Screening Questionnaire (RHSQ). It is an 8-item tool designed by the COPD Questionnaire Study Group from a cross-sectional study of primary care patients ≥40 years old from the United Kingdom and the United States with a history of smoking but no prior respiratory diagnosis. It could be used as a filtering tool to select patients at high risk of COPD. It is composed of three COPD-related items (breathlessness, productive cough, and activity limitation) and one question, each regarding smoking history and age.\cite{11} LFQ: The Lung Function Questionnaire (LFQ) is a simple, brief, self-administered instrument, being developed to address the need for a screening tool to identify one patient with COPD (the lower the number better the yield).
**Combined screening tests**

The combined diagnostic test accuracy of a handheld flow meter along with a questionnaire was assessed in four studies\[10,15,18,19\]. However, the combined results for the diagnostic accuracy was reported by only two studies\[13,19\].

Sichletidis *et al.* found that the combined sensitivity of a screening questionnaire (CDQ) with a handheld flow meter was 74.4% (95% CI 64–83%), and specificity 97% (95% CI 95–98%). The NNV was reported as 98.5% for combined usage. This is suggestive of an improved diagnostic accuracy of screenings tests when used in combination, thereby potentially reducing number of diagnostic assessments required.

Likewise, Shirley *et al.* reported the combined results for screening questionnaire (COPD-PS) and handheld flow meter. The tests together yielded a sensitivity of 20% and specificity of 92.9%. The individual test accuracy of other two studies\[10,18\] has been aforementioned in the above sections.

**Discussion**

The rapid evidence synthesis is an update of an existing systematic review\[8\] examining the evidence on diagnostic accuracy of screening tests and overall we incorporated evidence from 15 studies. Of all the screening questionnaires, CDQ was the most extensively used screening tool and was found to have acceptable sensitivity and specificity. Combined usage of handheld flow meters and the CDQ questionnaire lead to higher sensitivity and specificity compared to the CDQ screening questionnaire alone when used under the supervision of trained nurses or general practitioners. A higher sensitivity and specificity of handheld flow meter (80% and 79.8%, respectively) alone when compared to COPD-PS questionnaire (20% and 78.6%, respectively) was also reported. These results indicate that the use of a simple, validated, easy to administer tool in primary healthcare context is an effective method to facilitate early diagnosis of patients at a risk of COPD. However, the use of handheld flow meter requires training, underlining the need for further investments on this regards, particularly in resource-scarce settings. However, it is expected that such an early diagnosis focused strategy would be more cost-effective than the current scenario wherein delayed diagnosis leads to high costs of treatment in the secondary and tertiary care sectors as well as high mortality and morbidity. Formal cost-effectiveness evaluations might be mandated. There are, however, implementation challenges expected, including but not limited to addressing demand-side barriers, human resource and technical capacity issues, and issues around governance and financing. There is need for implementation research in the domain. There is also need for understanding care pathways for COPD in different countries to enable better planning.

We acknowledge the limitation of searching only in electronic databases with no search for identifying grey/unpublished literature and the lack of conduct of risk of bias assessment in this update but contend this would not change the findings of the study and its implications majorly.

**Conclusion**

The problem of misdiagnosis or underdiagnosis of COPD in primary care can be resolved through usage of handheld flow meters along with COPD questionnaires. There is need for more implementation research on this domain.

**Acknowledgements**

The authors would also like to acknowledge and thank Dr Prabir Chatterjee and Mr Narayan Tripathi, State Health Resource Centre, Chhattisgarh, India for placing the request to TGI-RES team to conduct a rapid review of the evidence.

**Financial support and sponsorship**

This gratis rapid evidence synthesis was made possible due to the support from World Health Organization, Alliance for Health Policy and Systems Research. The funder did not have a role in drafting, revising or approving the content of the policy brief.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2020.
2. Chronic obstructive pulmonary disease (COPD), Fact-sheets. World Health Organization. [Online] Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease (cOPD)?title=The%20Global%20Burden%20of%20Disease%20in%20low%20and%20middle-income%20countries. [Last accessed on 2020 Aug 8].
3. Global burden of disease (GBD) India compare [Online] Available from: http://www.healthdata.org/india. [Last accessed on 2020 Aug 8].
4. Office of the Registrar General Census Commissioner, Indian Census Bureau. Ministry of Home Affairs, Government of India, Census of India 2011 [Online] Available from: http://www.censusdata.org/india. [Last accessed on 2020 Sep 18].
5. Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 2004;350:2689-97.
6. Haroon S, Jordan R, Takwoingi Y, Adab P. Diagnostic accuracy of screening tests for COPD: A systematic review and meta-analysis. BMJ Open 2015;5:e008133.
7. Buffels J, Degryne J, Heyrman J, Decramer M; DIDASCO Study, Office spirometry significantly improves early detection of COPD in general practice: The DIDASCO Study. Chest 2004;125:1394-9.
8. Duong-Quy S, Hua-Huy T, Mai-Huu-Thanh B, Doan-Thi-Quynh N, Le-Quang K, Nguyen-Van H, et al. [Early detection of smoking related chronic obstructive pulmonary disease in Vietnam]. Rev Mal Respir 2009;26:267-74.
9. Freeman D, Nondyke RJ, Isonaka S, Nonikov DV, Maroni JM,
Tyagi, et al.: Diagnostic accuracy of screening tools for COPD in primary health care

Price D, et al. Questions for COPD diagnostic screening in a primary care setting. Respir Med 2005;99:1311-8.

10. Frith P, Crockett A, Beilby J, Marshall D, Attewell R, Ratnanesan A, et al. Simplified COPD screening: Validation of the PiKo-6(R) in primary care. Prim Care Respir J 2011;20:190-8.

11. Hanania NA, Mannino DM, Yawn BP, Mapel DW, Martinez FJ, Donohue JF, et al. Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ). Respir Med 2010;104:1160-70.

12. Kotz D, Nelemans P, van Schayck CP, Wesseling GJ. External validation of a COPD diagnostic questionnaire. Eur Respir J 2008;31:298-303.

13. Mintz ML, Yawn BP, Mannino DM, Donohue JF, Hanania NA, Grelet CA, et al. Prevalence of airway obstruction assessed by lung function questionnaire. Mayo Clin Proc 2011;86:375-81.

14. Price DB, Tinkelman DG, Nordyke RJ, Isonaka S, Halbert RJ; COPD Questionnaire Study Group. Scoring system and clinical application of COPD diagnostic questionnaires. Chest 2006;129:1531-9.

15. Sichletidis I, Spyros D, Papaioannou M, Chloros D, Tsiotsios A, Tsagaraki V, et al. A combination of the IPAG questionnaire and PiKo 6(R) flow meter is a valuable screening tool for COPD in the primary care setting. Prim Care Respir J 2011;20:184-9.

16. Thorén J, Tilling B, Lisspers K, Jörgensen L, Stenling A, Stratelis G, et al. Improved prediction of COPD in at-risk patients using lung function pre-screening in primary care: A real-life study and cost-effectiveness analysis. Prim Care Respir J 2012;21:159-66.

17. Casado V, Navarro SM, Álvarez AE, Villafañe M, Miranda A, Spaans N, et al. Laryngeal measurements and diagnostic tools for diagnosis of chronic obstructive pulmonary disease. Ann Fam Med 2015;13:49-52.

18. Llordés M, Zurdo E, Jaén A, Vázquez I, Pastrana L, Miravitlles M. Which is the best screening strategy for COPD among smokers in primary care? COPD 2017;14:43-51.

19. Shirley DK, Kaner RJ, Glesby MJ. Screening for chronic obstructive pulmonary disease (COPD) in an urban HIV clinic: A pilot study. AIDS Patient Care STDs 2015;29:232-9.

20. Spyros D, Haidich AB, Chloros D, Michalopoulou D, Sichletidis I. Comparison of three screening questionnaires for chronic obstructive pulmonary disease in the primary care. Respirat Med 2017;93:83-9.

21. Stanley AJ, Hasan I, Crockett AJ, van Schayck OC, Zwar NA. Validation of the COPD diagnostic questionnaire in an Australian general practice cohort: A cross-sectional study. Prim Care Respir J 2014;23:92-7.

22. Martinez FJ, Raczek AE, Seifer FD, Conoscenti CS, Curtice TG, D’Eletto T, et al. Development and initial validation of a self-scored COPD population screener questionnaire (COPD-PS). COPD 2008;5:85-95.

23. Hanania NA, Mannino DM, Yawn BP, Mapel DW, Martinez FJ, Donohue JF, et al. Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ). Respir Med 2010;104:1160-70.
APPENDICES

Appendix 1: Search strategies

Medline

| No. | Search terms                                                                                     |
|-----|-------------------------------------------------------------------------------------------------|
| #1  | Chronic obstructive pulmonary disease [MeSH] OR Chronic obstructive lung disease [MESH] OR Chronic obstructive airways disease [MESH] OR COPD[tw] OR COAD[tw] OR Emphysema[tw] OR “Chronic bronchitis”[tw] OR “Airflow obstruction”[tw] OR “Airflow limitation”[tw] |
| #2  | Secondary prevention [MESH] OR Spirometry [MESH] OR Design questionnaire [MESH] OR Decision aid [MESH] OR Algorithm [MESH] OR “Case finding”[tw] OR “Screening”[tw] OR “early detection”[tw] OR “Questionnaire”[tw] OR “Peak flow”[tw] OR “Chest X‑ray”[tw] OR Sensitivity[tw] OR Specificity[tw] |
| #3  | care, primary health[MeSH] OR primary health care*[tw] OR “primary health care”[tw]             |
| #4  | #1 AND #2 AND #3 Filters: English; Humans; Published in the 2014-2020                          |

EMBASE

| No. | Search terms                                                                                     |
|-----|-------------------------------------------------------------------------------------------------|
| #1  | Chronic obstructive pulmonary disease/de OR Chronic obstructive lung disease/de OR Chronic obstructive airways disease/de OR “COPD” OR “COAD” OR “Emphysema” OR “Chronic bronchitis” OR “Airflow obstruction” OR “Airflow limitation” |
| #2  | Secondary prevention/de OR Spirometry/de OR Design questionnaire/de OR Decision aid/de OR Algorithm/de OR “Case finding” OR “Screening” OR “early detection” OR “Questionnaire” OR “Peak flow” OR “Chest X‑ray” OR Sensitivity OR Specificity |
| #3  | “Primary health care/de OR primary health care* OR “primary health care”                        |
| #4  | #1 AND #2 AND #3 AND [embase]/lim NOT [medline]/lim AND [humans]/lim AND [2014‑2020]/py AND [english]/lim |

Appendix 2: PRISMA DTA CHECKLIST

| Section/topic | # PRISMA-DTA Checklist Item                                                                 | Reported on page # |
|---------------|---------------------------------------------------------------------------------------------|-------------------|
| TITLE/ABSTRACT|                                                                                             |                   |
| Title         | Identify the report as a systematic review (+/- meta-analysis) of diagnostic test accuracy (DTA) studies. | 1                 |
| Abstract      | Abstract: See PRISMA-DTA for abstracts.                                                      | 1                 |
| Rationale     | Describe the rationale for the review in the context of what is already known.               | 2                 |
| Clinical role of index test | State the scientific and clinical background, including the intended use and clinical role of the index test, and if applicable, the rationale for minimally acceptable test accuracy (or minimum difference in accuracy for comparative design). | 2                 |
| Objectives    | Provide an explicit statement of question (s) being addressed in terms of participants, index test (s), and target condition (s). | 2                 |
| METHODS       | Protocol and registration | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | NA                |
| Eligibility criteria | Specify study characteristics (participants, setting, index test (s), reference standard (s), target condition (s), and study design) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 2                 |

Contd...
| Section/topic                          | # | PRISMA-DTA Checklist Item                                                                 | Reported on page # |
|---------------------------------------|---|--------------------------------------------------------------------------------------------|-------------------|
| Information sources                   | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 3                 |
| Search                                | 8 | Present full search strategies for all electronic databases and other sources searched, including any limits used, such that they could be repeated. | 13                |
| Study selection                       | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 3                 |
| Data collection process               | 10| Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 3                 |
| Definitions for data extraction       | 11| Provide definitions used in data extraction and classifications of target condition (s), index test (s), reference standard (s) and other characteristics (e.g. study design, clinical setting). | 3                 |
| Risk of bias and applicability        | 12| Describe methods used for assessing risk of bias in individual studies and concerns regarding the applicability to the review question. | NA                |
| Diagnostic accuracy measures          | 13| State the principal diagnostic accuracy measure (s) reported (e.g. sensitivity, specificity) and state the unit of assessment (e.g per-patient, per-lesion). | NA                |
| Synthesis of results                  | 14| Describe methods of handling data, combining results of studies and describing variability between studies. This could include, but is not limited to: a) handling of multiple definitions of target condition. b) handling of multiple thresholds of test positivity, c) handling multiple index test readers, d) handling of indeterminate test results, e) grouping and comparing tests, f) handling of different reference standards | 4                 |
| Meta-analysis                         | D2| Report the statistical methods used for meta-analyses, if performed.                       | NA                |
| Additional analyses                   | 16| Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | NA                |

### RESULTS

| Study selection                          | 17| Provide numbers of studies screened, assessed for eligibility, included in the review (and included in meta-analysis, if applicable) with reasons for exclusions at each stage, ideally with a flow diagram. | 4                 |
| Study characteristics                    | 18| For each included study provide citations and present key characteristics including: a) participant characteristics (presentation, prior testing), b) clinical setting, c) study design, d) target condition definition, e) index test, f) reference standard, g) sample size, h) funding sources | 5                 |
| Risk of bias and applicibility          | 19| Present evaluation of risk of bias and concerns regarding applicability for each study. | NA                |
| Results of individual studies           | 20| For each analysis in each study (e.g. unique combination of index test, reference standard, and positivity threshold) report 2×2 data (TP, FP, FN, TN) with estimates of diagnostic accuracy and confidence intervals, ideally with a forest or receiver operator characteristic (ROC) plot. | 5,6               |
| Synthesis of results                    | 21| Describe test accuracy, including variability; if meta-analysis was done, include results and confidence intervals. | 7,8               |
| Additional analysis                     | 23| Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression; analysis of index test: failure rates, proportion of inconclusive results, adverse events). | NA                |

### DISCUSSION

| Summary of evidence                     | 24| Summarize the main findings including the strength of evidence. | 9                 |
| Limitations                             | 25| Discuss limitations from included studies (e.g. risk of bias and concerns regarding applicability) and from the review process (e.g. incomplete retrieval of identified research). | 9                 |
| Conclusions                             | 26| Provide a general interpretation of the results in the context of other evidence. Discuss implications for future research and clinical practice (e.g. the intended use and clinical role of the index test). | 9                 |

### FUNDING

| Funding                                | 27| For the systematic review, describe the sources of funding and other support and the role of the funders. | 10                |

Adapted from Mclnnes MD, Moher D, Thoms B, McGrath TA, Bovbey PM. The PRISMA-DTA Group (2018). Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018 Jan 23;319 (4):388-396. doi: 10.1001/jama.2017.19163.
## Appendix 3: Characteristics of included studies

| Study | Country | Setting | Recruitment method | Eligibility criteria | Index and reference tests | Definition of COPD |
|-------|---------|---------|--------------------|----------------------|--------------------------|-------------------|
| Buffels 2004 Belgium | 20 general practitioners | Invited patients routinely attending general practice over a 12-week period in 1999. | Inclusion criteria: Age 35-70 years Exclusion criteria: Receiving bronchodilators and/or inhaled corticosteroids | Index test: Screening questionnaire Reference test: Pre-BD spirometry in all subjects with respiratory symptoms and 10% sample of asymptomatic subjects | Pre-BD FEV1/FVC <88.5% predicted for men & FEV1/FVC <89.3% for women |
| Duong-Quy 2009 Vietnam | 12 primary care medical centres in one city | Broadcast an advertisement on the local television daily for one week. A recruitment company was used to help with participant recruitment (details not reported). Eligible subjects expressing an interest in participating were advised to attend one of the 12 primary care centres from January 2007 to February 2008. | Inclusion criteria: Active and former smokers with >10 pack-years and aged >40 years Exclusion criteria: Previously diagnosed respiratory disease (asthma, COPD and tuberculosis) | Index test: Pre-BD handheld flow meter (Piko-6®) Reference test: Full medical assessment including clinical examination, pulmonary radiology, ECG, and post-BD spirometry for those who had an index FEV1/FEV6 <0.7 and a sample of those with FEV1/FEV6 ≥0.7 | Post-BD FEV1/FEV6 <0.7 with <200 mL or 12% reversibility |
| Casado 2015 Spain | Primary care centre | Random sampling of a general population | Inclusion criteria: Population aged between 40 to 75 years | Index test: Screening questionnaire Reference test: Pre-/Post BD Spirometry on all subjects | Post-BD Ratio of FEV1/FVC (forced expiratory volume in 1 second/forced vital capacity) of <0.7 Post-BD FEV1/FEV6 <0.7 and lack of reversibility (reversibility defined as increase in FEV1 of 200mL and 15% from pre-BD FEV1 (not clear if all were post-BD) |
| Freeman 2005 UK | One general practice | Postal invitation from October 1997 to April 2002. | Inclusion criteria: Age ≥40 years & current/ex-smoker & had either received respiratory medications in the preceding 2 years or had a history of asthma Exclusion criteria: None | Index test: Screening questions Reference test: Pre-/post-BD spirometry on all subjects | Post-BD FEV1/FEV6 <0.7 |
| Frith 2011 Australia | 4 primary care practices | Recruited during routine practice visits, invitation to study days, and local newspaper advertisement between August and December 2006. | Inclusion criteria: Age ≥50 years & current/ex-smoker & no prior diagnosis of obstructive lung disease (COPD, emphysema, chronic bronchitis, asthma) & no treatment for obstructive lung disease in past 12 months Exclusion criteria: Refusal or inability to give consent, pre-existing non-obstructive lung disease, symptoms suggestive of unstable heart disease, and spirometry contraindications | Index test: Pre-BD handheld flow meter (Piko-6®) & screening questionnaire (COPD Diagnostic Questionnaire) Reference test: Pre-/post-BD spirometry on all patients | Post-BD FEV1/FEV6 <0.7 |
| Hanania 2010 US | Two family physician group offices | Invited patients aged ≥40 years visiting the practices from March-May 2008 | Inclusion criteria: Age ≥40 years Exclusion criteria: None | Index test: Screening questionnaire (Lung Function Questionnaire) Reference test: Pre-BD spirometry | Pre-BD FEV1/FEV6 <0.7 |

Contd...
| Study | Country | Setting | Recruitment method | Eligibility criteria | Index and reference tests | Definition of COPD |
|-------|---------|---------|-------------------|---------------------|--------------------------|-------------------|
| Kotz\cite{12} 2008 | Netherlands | General population and primary care practices | Advertisements in a local newspaper, flyers, posters and mailings to households and invitation during primary care consultations from Jan 2005-Dec 2006. | Inclusion criteria: Age 40-70 years & current smoker with ≥10 pack years & motivated to stop smoking & able to read and speak Dutch & reporting a respiratory symptom (cough, phlegm or dyspnoea) Exclusion criteria: Prior respiratory diagnosis, spirometry in previous 12 months or contraindications to smoking cessation therapy | Index test: Questionnaire (COPD Diagnostic Questionnaire) Reference test: Pre-/post-BD spirometry in all participants | Post-BD FEV1/FVC <0.7 |
| Llordes\cite{18} 2016 | Spain | 8 primary care centres | Active, Patient who attended the primary care centre for any reason during the study period were invited to participate. | Inclusion criteria: Subjects over the age of 40 years who were smokers or ex-smokers of at least 1 pack-year with no previous diagnosis of COPD and who attended the Primary Care centres for any reason. | Index test: Screening questionnaire (CDQ/Respiratory Health Screening Questionnaire (RHSQ) COPD-population screener (PS) Two screening questions (2SQ)); Handheld spirometer (Vitalograph COPD-6), Reference test: Pre and Post BD Spirometry | Post-bronchodilator FEV1/FVC <0.7 |
| Mintz\cite{13} 2011 | US | 36 primary care centres | NR | Inclusion criteria: Age ≥30 years old & current/ex-smoker Exclusion criteria: Regular use of respiratory medications within 4 weeks of the study, known diagnosis of substantial lung conditions with regular use of respiratory medications. | Index test: Screening questionnaire (Lung Function Questionnaire) Reference test: Pre-/post-BD spirometry | LFQ ≤ 18 & post-BD FEV1/FVC <0.7 |
| Price\cite{4} 2006 | UK & US | 2 primary care practices | Postal invitation | Inclusion criteria: Age ≥40 years & current/ex-smoker Exclusion criteria: Refusal to consent, history of non-obstructive lung disease, use of respiratory medications in past year, acute symptoms of unstable heart disease | Index test: Screening questionnaire (COPD Diagnostic Questionnaire) Reference test: Pre-/post-BD spirometry | Post-BD FEV1/FVC <0.7 |
| Shirley\cite{19} 2015 | Japan | 2 HIV primary care clinics | Subjects were recruited via referral from clinic providers and staff, and via response to flyers posted in the waiting rooms. | Inclusion criteria: Patients who met inclusion criteria (age ≥ 35 years with documented HIV infection) were screened for entrance to the study. | Index test: Screening questionnaire (COPD-PS); Peak flow meter (Vitalograph asma-1 electronic peak flow meter) Reference test: Pre and Post BD Spirometry | Post-BD FEV1/FVC <0.7 |

**Contd...**
| Study         | Country  | Setting                      | Recruitment method                                                                 | Eligibility criteria                                                                                     | Index and reference tests                                                                 | Definition of COPD                                                                 |
|--------------|----------|------------------------------|------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| Sichletidis  | Greece   | 25 general practices         | Invited first 50 patients meeting the inclusion criteria who visited each participating GP from 1st March-31st May 2009. | Inclusion criteria: Age >40 years<br>Exclusion criteria: Confirmed diagnosis of lung disease, thoracic surgery in previous 6 months, acute respiratory infection, uncontrolled cardiac disease, or could not perform acceptable spirometry | Index tests:<br>1. Screening questionnaire (International Primary Airways Group Questionnaire, also known as the COPD Diagnostic Questionnaire)<br>2. Post-BD handheld flow meter (Piko-6®) (Bronchodilator = 400μg salbutamol)<br>Reference test: Pre-/post-BD spirometry | Post-BD FEV1/FVC <0.7                                                                       |
| Spyraatos     | Greece   | Primary care clinics         | The general population were invited to participate in the present study by advertisement posters that had been distributed across a network of primary care practices in the city | Inclusion criteria: Participants eligible for this cross-sectional study were subjects aged >40 years, current and former smokers (≥10 pack-years).<br>Exclusion criteria: A previous medical diagnosis of bronchial asthma or chronic pulmonary disease other than COPD (e.g., bronchiectasis, lung cancer, tuberculosis, and interstitial lung disease). | Index test: Screening questionnaire (CDQ/International Primary Care Airways Group (IPAG) questionnaire; COPD Population Screener (COPD-PS) questionnaire; Lung Function Questionnaire (LFQ))<br>Reference test: Pre and Post BD Spirometry | Post-BD FEV1/FVC <0.7                                                                        |
| Stanley       | Australia | 36 general practices         | Patients aged 40-85 years who were former or current smokers with no previous diagnosis of COPD or other obstructive lung disease were invited to a case-finding appointment with a practice nurse in one of the 36 study general practices. | Inclusion criteria: Patients aged 40-85 years who were former or current smokers with no previous diagnosis of COPD or other obstructive lung disease. | Index test: Screening questionnaire (COPD Diagnostic Questionnaire (CDQ))<br>Reference test: Pre and Post BD Spirometry | post-BD forced expiratory volume in one second/forced vital capacity (FEV1/FVC) ratio <0.7, |
| Thorn         | Sweden   | 21 primary healthcare centres | Invited patients attending participating primary healthcare centres over a 5-month period. | Inclusion criteria: Age 45-85 years & current/ex-smoker with ≥15 pack years<br>Exclusion criteria: None | Index test: Pre-BD handheld flow meter (COPD-6)<br>Reference test: Pre-/post-BD spirometry | Post-BD FEV1/FVC <0.7                                                                       |

BD, bronchodilator; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; CDQ, COPD Diagnostic Questionnaire; COPD-PS, COPD Population Screener questionnaire; LFQ, Lung Function Questionnaire; IPAG, International Primary Airways Group.